Topic: #biotechnology

Corvus Pharmaceuticals Advances Oral ITK Inhibitor in Multiple Diseases

On August 6, Corvus Pharmaceuticals (CRVS) reported its second-quarter earnings, highlighting the progress of its oral ITK inhibitor, soquelitinib. The drug is being tested across five diseases, including a rare blood ca

2d agopharmaceuticalsclinical-trials

Greenhaven Road Capital Investments: AnaptysBio (ANAB) and GSK Acquisition Speculation

Investment management firm Greenhaven Road Capital has added biotechnology company AnaptysBio, Inc. (NASDAQ: ANAB) to its portfolio. The company focuses on immunology therapeutics for autoimmune and inflammatory diseases

2d agobiotechnologyinvestments